Background: Pyruvate has been shown to increase contractile function in isolated myocardium and to improve hemodynamics in patients with congestive heart failure. We tested the hypothesis that pyruvate potentiates the inotropic response to b-adrenergic stimulation and to elevated extracellular calcium, since this may be of potential therapeutic value in the clinical setting of acute heart failure in order to circumvent deleterious effects on energy demand as can occur during catecholamine therapy. Methods and Results: We investigated isometrically contracting isolated multicellular muscle preparations from terminal failing human hearts at 378C, pH 7.4, and a stimulation frequency of 1 Hz. At an extracellular calcium concentration of 1.25 mM, pyruvate (10 mM) alone increased developed force (F ) from revealed that altered myofilament responsiveness and / or sarcoplasmic reticulum (SR) calcium load must underlie the positive inotropic effect of pyruvate. Conclusion: A combination of pyruvate and b-adrenergic stimulation may be of therapeutic value in acute heart failure by reducing the concentrations of potential deleterious catecholamines that are currently necessary to maintain adequate tissue perfusion.
Introduction
a variety of inotropic agents including catecholamines, calcium-sensitizing agents, phosphodiesterase-inhibitors, Congestive heart failure still remains a therapeutic and calcium, enhanced inotropy is achieved via increased dilemma, which frequently demands the administration of ATP-consumption [1] [2] [3] . If the additional force / pressure potential harmful adrenergic agents to maintain adequate production is gained in parallel with an over-proportional tissue perfusion. Enhancement of cardiac contractility is ATP-cost, this will result in a worsening of economy of most commonly achieved by means of b-adrenergic stimucontraction. This scenario may be of particular importance lation using intravenous catecholamines, i.e. dopamine, in medium-to high-dose catecholamine therapy of terminal dobutamine, epinephrine, norepinephrine, or combinations congestive heart failure or ischemic-stunned myocardium. thereof. The therapeutic goal of restoring adequate tissue It has been reported that the glycolytic intermediate perfusion by increasing cardiac output may be partially pyruvate exerts positive-inotropic effects and improves offset by increased oxygen consumption and induction of contractile function in healthy and diseased canine and potential harmful arrhythmias. It has been reported that for swine hearts in vivo [4] [5] [6] [7] , in in vitro perfused rabbit hearts [8] , in isolated rat myocytes [9] and in isolated multicellular muscle preparations from failing human hearts [10] . Furthermore, pyruvate improves hemodymonoxime (BDM) as a cardioprotective agent [21] . This namics in patients with congestive heart failure [11] .
solution was in equilibrium with 95% O / 5% CO , 2 2 Several mechanisms have been postulated underlying the resulting in a pH of 7.4. From these hearts, small, free positive inotropic effect of pyruvate. The predominant running and unbranched trabeculae were dissected (n527) actions of pyruvate include an increase in the cytosolic as previously described [22, 23] . With the aid of a stereo phosphorylation potential [ATP] /([ADP]3[P ]), a modulamicroscope the dimensions of the preparations were meai tion of pH and cytosolic redox state and a reduction of sured at 403 magnification (resolving power |10 mm). inorganic phosphate [8, [12] [13] [14] . Pyruvate therefore may act Preparations were mounted in the experimental set-up in via an increased thermodynamic driving force of the the BDM-containing K-H solution, which was immediately sarcoplasmic (SR) calcium pump, leading to an increased switched to a K-H solution without BDM. Average SR calcium gradient [15] and hence an increased calciumdimensions of the preparations included in the data were release during contraction.
374631 mm in width, 305624 mm in thickness, and It has been previously shown that in stunned guinea pig 24396179 mm in length (n527). myocardium [16] and in healthy rabbit myocardium, pyruvate potentiates b-adrenergic inotropism [17] . How-2.2. Experimental apparatus and protocol ever, presently no data are available from diseased human myocardium and it is unknown whether the results from Muscles were mounted using two blocks of ventricular healthy rabbit myocardium are applicable to the failing tissue at both ends of the longitudinal preparation axis in human heart. A potentiated b-adrenergic response may be the experimental set-up between a basket-shaped extension of particular importance in heart failure which is well [22, 24] of a force transducer (KG-4, Scientific Instruments, characterized by a severely impaired b-adrenergic response Heidelberg, Germany) and a hook connected to a micro- [18] [19] [20] . As a new approach to potentially reduce the displacement device. Failing human heart tissue was obtained from explanted mN / mm . This muscle length reflects a sarcomere length hearts of patients undergoing heart transplantation for endof |2.1-2.2 mm [24, 25] . Under these conditions timestage congestive heart failure: four patients suffered from dependent deterioration of contractility could be miniischemic cardiomyopathy and five from idiopathic dilative mized. The muscles were left contracting under these cardiomyopathy. A total of 14 preparations were taken conditions for at least an additional 45 min to equilibrate. from the left ventricle, and 13 from the right ventricle.
After equilibration, a concentration response curve of Average data of developed force during an isoproterenol concentration- response at all different isoproterenol concentrations, i.e. the isoPyruvate increases twitch timing parameters, and isoproterenol shortens proterenol-induced force increase was larger in the presence of pyruvate.
the isometric twitch, whereas the combination of both agents partially (B) Addition of 10 mM pyruvate induced a significant increase in force counterbalances these opposite effects. Inset: same data depicted normalunder maximal stimulating isoproterenol-concentrations (1 mM).
ized to individual peak force. * Denotes a significant increase compared to baseline measurements without application of pyruvate (P,0.05). The contractile and twitch timing parameters are given of the individual effects (P,0.05). Thus, the isoproterenolin Table 1 . Isoproterenol decreased time to peak tension induced enhancement of contractility was potentiated by and relaxation times significantly. In contrast, pyruvate pyruvate. Addition of 10 mM pyruvate to saturating increased twitch timing parameters, while the combination isoproterenol concentrations (1 mM) still induced a signifiof pyruvate and isoproterenol counter-balanced the effects cant increase in F , as shown in Fig. 2B . To exclude dev on twitch timing to a certain extent which is shown in Fig. concentration-dependent effects of pyruvate, we repeated 3. Remarkably, diastolic force / tension decreased slightly the experiments with the addition of 3 mM pyruvate (n54) with pyruvate application alone or in combination with and observed less pronounced but still potentiating effects isoproterenol (P,0.05). of pyruvate on isoproterenol-enhanced inotropy: pyruvate 2 Sensitivity of the preparations to isoproterenol stimula-(3 mM) increased F alone by 3.661.8 mN / mm (P5 dev tion was calculated from the concentration-response NS) and isoproterenol (1 mM) alone by 15.164.0 mN / remained unchanged.
curves of the individual experiments (Fig. 4) . Pyruvate mM pyruvate on top of the calcium concentration-resensitized the effect of isoproterenol on F significantly: sponse curve could further increase F (Fig. 5C ). to 50% relaxation; TTP, time to peak tension; TT , time from stimulation to 90% relaxation. 4. Discussion ning of energy demand, increasing oxygen need and induction of potentially harmful arrhythmias [2, 3] . CoThe present study indicates that a combined inotropic administration of catecholamines and pyruvate could therestimulation of failing human myocardium with the bfore reduce the necessary therapeutic dose of adrenergic adrenergic agonist isoproterenol and the glycolytic interagents which in turn would imply less frequent sidemediate pyruvate results in an overproportional increase in effects. contractile performance than can be calculated by a mere Under conditions of maximal b-adrenergic stimulation, addition of the individual inotropic effects. This indicates addition of pyruvate could further increase developed that pyruvate is capable of potentiating the b-adrenergic force. This indicates that pyruvate acts independently of inotropic response in failing human heart, whereas the b-receptor-G-protein-adenylate cyclase pathway. Addition combination of elevated extracellular calcium and pyruvate of pyruvate at higher inotropic baseline conditions resulted seems to exhibit additive, not potentiating, effects. These in enhanced rapid cooling contractures. Instantaneous results may be of particular interest in the clinical setting cooling of the preparation induces a complete release of of acute heart failure, where inotropic stimulation with the calcium from the SR into the cytosol, resulting in a medium-to high-dose catecholamines is frequently inevitsteady state activation of the myofilaments [26, 27] . The able despite their well known side-effects including worseincrease observed in these rapid cooling contractures indicates that part of the positive inotropic effect of pyruvate is mediated either via (i) increased calcium release of the SR (either absolute or fractional increase), (ii) increased myofilament calcium sensitivity, or (iii) alterations in cross bridge kinetics of the myofilaments. Previous work has shown that increased SR calcium load is associated with increased calcium transients [9, 10] . Together with increased isometric force development at maximal inotropic calcium concentrations, this may be explained by an increased V of the SR calcium pump max and subsequently enhanced trans-SR gradient [15] . Previous work has suggested that pyruvate acts in part through thermodynamic stimulation of the SR calcium pump due to an increase of the phosphorylation potential [ATP] / we conclude that the inotropic effect of pyruvate is not mM pyruvate, twitch force is higher (positive inotropic effect), as is the exclusively mediated via elevated SR calcium content.
amplitude of the cooling contracture, reflecting an increase in SR calcium load.
Either pyruvate causes an increase of fractional SR cal- negative impact on SR calcium handling and contractile over-proportional amount of ATP consumption, economy performance [29] . Thus, a decrease in [P ] would agree of contraction worsens. This scenario is an inherent i with our finding that part of the inotropic effect could be drawback of catecholamine treatment in acute heart failure. mediated via a modulation of calcium kinetics and / or Beta-adrenergic stimulation induces a desensitization of cross bridge cycling kinetics.
the myofilaments for calcium through phosphorylation of The potentiating increase in force development with the troponin-I [32] and removes the SR calcium ATPase combination of isoproterenol and pyruvate is interpreted as inhibition through phosphorylation of phospholamban [33] . a potentiation of b-adrenergic response by pyruvate.
Thus, a substantial fraction of the increased calcium is Furthermore, we demonstrated a slight increase in iso-'wasted' to overcome the desensitization of the myofilaproterenol-sensitivity after pyruvate administration. These ments. Additionally, increased futile cycling may occur data are consistent with recent work on stunned guinea pig under increased cAMP levels, adding to the 'wasted myocardium where pyruvate blunted the energy depletion energy' under catecholamine stimulation [34] . These produe to high concentrations of isoproterenol [16] , and on cesses are achieved by an increased ATP-cost, reflected by healthy rabbit myocardium where we observed a similar an overproportional increase in oxygen consumption and / potentiation of the b-adrenergic response [17] . These or heat production in relation to the accompanying increase results are even more remarkable in light of the reduced in developed force / pressure as has been shown in animal b-adrenergic response in failing human heart due to b- [2, 35] and human myocardium [36] . Pyruvate, as a receptor downregulation and / or internalization [19, 20] .
prototype of an energetic stimulating agent, affects energy Compared to data from healthy animal myocardium with metabolism by its input into the tricarboxylic-acid cycle the intact b-adrenergic system as the most powerful (Krebs cycle). The effects of pyruvate seem unique and inotropic mechanism, it could have been expected that the possibly unrelated to the fact that it is a metabolic fuel; interaction of isoproterenol and pyruvate would, at best, administration of other substrates (acetate, lactate) does not result in an additive effect. Consequently, pyruvate-inexert strong inotropic effects [17, 37] . The beneficial action duced potentiation of inotropic b-adrenergic effects in the of glucose-insulin-potassium in patients with myocardial setting of heart failure with impaired b-adrenergic system infarction may be partly attributed to increased glycolytic points again to a more downstream mode of action.
flux with subsequent generation of pyruvate [38] [39] [40] . Another observation concerning the time course of force development after addition of pyruvate (10 mM) needs to be addressed: a bi-phasic force behavior with an initial 5. Clinical implications decrease to 50-60% of the baseline value over several minutes was observed in all experiments. Subsequently, A combination of pyruvate with b-adrenergic agents F slowly but continuously increased over the next 10-dev could possibly ameliorate the deleterious energetic effects 25 min to a new plateau higher than the initial baseline of high dose catecholamines and result in a better economy force value. This initial drop in contractility may be of contraction than is the case with hemodynamically potentially detrimental in patients with acute heart failure, equivalent therapeutic doses of a b-agonist monotherapy. however, in a recent clinical study in patients with stable Co-administration of pyruvate could allow reduced catchronic congestive heart failure, we observed no negative echolamine doses without attenuating the therapeutic efimpact of pyruvate administration on invasive hemodyficacy. It may be speculated that the addition of pyruvate namics [11] . The transient negative inotropic effect could might even help to avoid tolerance phenomena of continube explained by temporary acidifying of the cytoplasm due ous high dose catecholamine treatment. tricles: uniform regional distribution, but no increased internaliza-
